semaglutide 6 months Month Progress Semaglutide Monthly Membership - 6

It plays a key role in muscle repair, growth and regeneration, making it ideal for individuals focused on strength, hypertrophy and recovery

We will need to wait and see how the final labeling looks for full information

Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A

The process occurs in two distinct phases

Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters

It also has a boxed warning and is labeled by the FDA as a most serious medication warning because it causes risk of thyroid C-cell tumors